Vertex Pharmaceuticals — Q2 2023 Form 10-Q
Business context and period. The unaudited report covers the quarter and six months ended June 30, 2023. Vertex is a single-segment pharmaceutical company whose revenues are primarily from cystic fibrosis (CF) medicines. Its pipeline includes programs in sickle cell disease, beta thalassemia, pain, kidney disease, type 1 diabetes and other conditions.
Financial results
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Product revenue | $2.493B | $2.196B | $4.868B | $4.294B |
| Operating income | $1.026B | $1.106B | $1.805B | $2.147B |
| Net income | $915.7M | $810.5M | $1.616B | $1.573B |
| Diluted EPS | $3.52 | $3.13 | $6.21 | $6.09 |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $2.034B | $2.096B |
- TRIKAFTA/KAFTRIO revenue was $2.240B in Q2, up 18%; first-half revenue was $4.337B, up 19%. Other CF product revenues declined, primarily as patients switched to TRIKAFTA/KAFTRIO.
- Q2 U.S. revenue grew 7% to $1.508B; ex-U.S. revenue grew 26% to $985.4M. For the first half, U.S. revenue rose 5% and ex-U.S. revenue rose 30%.
- Cost of sales was 12% of product revenue in both Q2 and the first half, unchanged from 2022. The filing does not provide a separate gross-margin figure.
- Operating costs and expenses rose 35% in Q2 and 43% in the first half. R&D increased 31% and 27%, respectively; acquired in-process R&D (AIPR&D) was $110.5M in Q2 and $457.6M in the first half.
- Cash, cash equivalents and marketable securities totaled $12.594B at June 30, up from $10.891B at year-end. Working capital was $10.521B. The company reported $10.151B of cash and cash equivalents and $2.443B of marketable securities.
- First-half investing cash outflow was $2.138B, primarily reflecting purchases of marketable securities; financing cash outflow was $277.4M. Vertex repurchased $161.1M of shares in the first half, with $2.8B of authorization remaining.
- The $500M revolving credit facility was undrawn; Vertex reported compliance with its covenants. Balance-sheet finance lease liabilities were $404.1M long term; the filing does not identify other funded borrowings.
Material changes and unusual items
- Revenue growth was led by TRIKAFTA/KAFTRIO and international markets. Despite higher revenue, operating income fell 7% in Q2 and 16% in the first half, mainly as R&D, AIPR&D and SG&A spending increased.
- First-half 2023 AIPR&D included $225.1M paid to Entrada, $100M paid to CRISPR, and a $70M CRISPR research milestone. The milestone is payable in Q3. First-half 2022 AIPR&D was primarily a $60M Catalyst payment.
- Net income increased 13% in Q2 and 3% in the first half, supported by substantially higher interest income as rates and invested balances rose. Other income/expense also improved versus 2022, when strategic equity investment losses were significant; this item remains volatile.
- First-half operating cash flow was slightly lower year over year despite higher net income, including cash uses from accounts receivable and inventory growth.
Outlook, commentary and risks
- Management expects existing cash, investments and product-sale cash flows to fund operations for at least the next 12 months. No numeric full-year revenue or EPS guidance is provided in the filing text.
- Exa-cel regulatory applications for sickle cell disease and transfusion-dependent beta thalassemia were under review. FDA action dates were December 8, 2023 for sickle cell disease and March 30, 2024 for beta thalassemia; the FDA planned an advisory committee meeting for exa-cel.
- Management expected to complete pivotal trials of once-daily vanzacaftor combination therapy and VX-548 for acute pain by year-end 2023. These are forward-looking expectations, not assured outcomes.
- Key disclosed risks include clinical and regulatory uncertainty, the possibility of trial delays or failure, manufacturing and supply-chain demands (especially for cell and gene therapies), reimbursement and market access, and volatility in strategic equity investments. Management said risk factors had not materially changed from the 2022 Form 10-K.
- The company reported no material legal proceedings and no material contingent liabilities accrued, other than contingent consideration. Exonics-related contingent consideration was $126.5M; its valuation depends on uncertain development and regulatory milestones and could change materially.
Important facts for investors to verify
- Whether TRIKAFTA/KAFTRIO growth and ex-U.S. reimbursement and launches continue to offset declines in other CF products.
- Regulatory decisions and launch readiness for exa-cel, including FDA review timelines and any advisory committee outcome.
- Whether rising R&D, launch-support and collaboration spending translates into pipeline progress without sustained pressure on operating income and cash generation.
- How much of the remaining $2.8B repurchase authorization is used, and the effect on cash and share count.
- Changes in interest income, strategic equity investment values, contingent consideration estimates and other items that may make reported earnings volatile.